Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5821756 | Antiviral Research | 2016 | 10 Pages |
Abstract
To investigate the feasibility and efficacy of a virus-like particle (VLP) vaccine composed of the conserved antigenic epitopes of respiratory syncytial virus (RSV), the chimeric RSV VLPs HBcÎ-tG and HBcÎ-tG/M282-90 were generated based on the truncated hepatitis B virus core protein (HBcÎ). HBcÎ-tG consisted of HBcÎ, the conserved region (aa 144-204) of the RSV G protein. HBcÎ-tG was combined with a single peptide (aa 82-90) of the M2 protein to generate HBcÎ-tG/M282-90. Immunization of mice with the HBcÎ-tG or HBcÎ-tG/M282-90 VLPs elicited RSV-specific IgG and neutralizing antibody production and conferred protection against RSV infection. Compared with HBcÎ-tG, HBcÎ-tG/M282-90 induced decreased Th2 cytokine production (IL-4 and IL-5), increased Th1 cytokine response (IFN-γ, TNF-α, and IL-2), and increased ratios of IgG2a/IgG1 antibodies, thereby relieving pulmonary pathology upon subsequent RSV infection. Our results demonstrated that chimeric HBcÎ-tG/M282-90 VLPs represented an effective RSV subunit vaccine candidate.
Related Topics
Life Sciences
Immunology and Microbiology
Virology
Authors
Lei Qiao, Yuan Zhang, Feng Chai, Yiluo Tan, Chunling Huo, Zishu Pan,